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Abstract
Background: Recently, the anti-tumor activity of N-myc downstream-regulated gene 2 (NDRG2) was shown
decreased expression in clear cell renal cell carcinoma (CCRCC), but the role of the down-expression of NDRG2 has
not been described.
Methods: The NDRG2 recombinant adenovirus plasmid was constructed. The proliferation rate and NDRG2 expression
of cell infected with recombinant plasmid were mesured by MTT, Flow cytometry analysis and western blot.
Results: The CCRCC cell A-498 re-expressed NDRG2 when infected by NDRG2 recombinant adenovirus and
significantly decreased the proliferation rate. Fluorescence activated cell sorter analysis showed that 25.00% of cells
expressed NDRG2 were in S-phase compared to 40.67% of control cells, whereas 62.08% of cells expressed NDRG2
were in G1-phase compared to 54.39% of control cells (P < 0.05). In addition, there were much more apoptotic
cells in NDRG2-expressing cells than in the controls (P < 0.05). Moreover, upregulation of NDRG2 protein was
associated with a reduction in cyclin D1, cyclin E, whereas cyclinD2, cyclinD3 and cdk2 were not affected examined
by western blot. Furthermore, we found that p53 could upregulate NDRG2 expression in A-498 cell.
Conclusions: We found that NDRG2 can inhibit the proliferation of the renal carcinoma cells and induce arrest at
G1 phase. p53 can up-regulate the expression of NDRG2. Our results showed that NDRG2 may function as a tumor
suppressor in CCRCC.
Background
Renal cell carcinoma (RCC) accounts for 3% of all
malignant tumors and 90% of neoplasms arising from
the kidney. The incidence rates vary more than 10-fold
around the world; rates are higher in Western countries
than in Asia. In the United States, renal cancer is the
7th leading malignant condition among men and the
12th among women [1]. Clear cell renal cell carcinoma
(CCRCC) originates from proximal tubule cells and is
the most common pathological type of renal cell carci-
noma. Multiple genetic changes have been found in
CCRCC, but little is known about major tumor suppres-
sor genes involved in the tumorigenesis of the disease.
N-myc downstream regulated gene 2 (NDRG2)
belongs to the NDRG family, which is comprised of 4
members, NDRG1-4, and is expressed in the tissues of
the brain, heart, skeletal muscle, and kidney [2]. NDRG2
was identified through sequence homology and is impli-
cated in cell growth, differentiation and neurodegenera-
tion [3-6]. It has been proposed that NDRG2 is a
candidate tumor suppressor gene since it induces apop-
tosis in certain cancer cells and mRNA was down-regu-
lated or absent in several human cancers and cancer
cell-lines [3,7,8]. In addition, higher expression of
NDRG2 mRNA correlated with clinically less aggressive
tumors in meningiomas [8] and NDRG2 expression in
high-grade gliomas was positively correlated with survi-
val [9].
Until now, a mechanism for the inactivation of
NDRG2 in cancer cells has not been described. In pre-
vious studies, we found that the expression level of
NDRG2 mRNA and protein were down-regulated in
renal tissue and CCRCC [10], indicating that NDRG2
might play an important role in the carcinogenesis and
development of CCRCC. In the present work, we found
that forced expression of NDRG2 can inhibit the prolif-
eration of the renal carcinoma cells and induce arrest at
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NDRG2. Our results showed that NDRG2 may function
as a tumor suppressor in CCRCC.
Methods
Construction of recombinant adenovirus
The 1.2 kb NDRG2 gene was released from pET44a-
NDRG2 plasmid (provided by Dr. Wei Zhang) by Sal
I—Hind III restriction enzyme digestion, and inserted
into the same site of plasmid pAdTrack-CMV, resulting
in plasmid pAdTrack-NDRG2.
pAdTrack-NDRG2 was linearized with PmeI and
transfected into Escherichia coli BJ5183 cells together
with pAdEasy-1 (Stratagene Holding Corporation, La
Jolla, CA, USA) by electroporation, and the recombi-
nants were selected with kanamycin. The clonies were
picked, grown, and then plasmids were extracted,
screened and analyzed by agarose gel electrophoresis,
and one named AdEasy-GFP-NDRG2 selected. The con-
struction of recombinant adenovirus AdEasy-GFP-
NDRG2 was performed as described by Tran et al [11].
Infectious viruses were purified by plaques. All recombi-
nant adenoviruses were amplified on human embryonic
kidney cell line 293 and purified by double cesium
chloride density gradient ultracentrifugation. Titers of
the adenoviral stocks were determined by plaque assay
on 293 cells. Photograph of viral plaque formation to
count viral titer (plaque assay). HEK-293 cells, which
grew confluently on the bottom of the 24-well plastic
plate (1.5 cm diameter each), were infected with serially
diluted solutions containing adenoviral virus, and then
cultured over night to make viral plaque. The number
of plaques indicates the number of the infectious virus
(= viral titer, as plaque forming unit). AdEasy-GFP-p53
was provided by Dr. Lintao Jia.
Cell Culture
The human renal clear-cell carcinoma lines A-498 and
the human embryonic kidney cell lines HEK-293 were
obtained from the American Type Culture Collection
(ATCC) and maintained as recommended. A-498 was
cultured in Minimum Essential Medium (MEM) with 2
mM L-glutamine and Earle’s BSS adjusted to contain 1.5
g/l sodium bicarbonate, 0.1 mM non-essential amino
acids, and 1.0 mM sodium pyruvate. HEK-293 was cul-
tured with Dulbecco’s Modified Eagles’ Medium
(DMEM). All the culture fluid was supplemented with
10% fetal calf serum (FCS) and all cells were cultured
with 5% CO2 at 37°C in a humidified chamber.
Western blot analysis
Cells were washed with ice-cold PBS and lysed in a
RIPA buffer [50 mM Tris (pH7.5), 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS] containing
PMSF (1 mM) and protease inhibitors (2 μg/ml; Pro-
tease Inhibitor Cocktail Set III, Calbiochem) on ice for
30 minutes. The lysates were clarified by centrifugation
at 13,000 × g for 30 minutes at 4°C. The total protein
concentration was estimated using Protein Assay Kit
(Bio-Rad, Richmond, CA). 30-80 μg protein samples
were loaded on a 12% SDS-PAGE and subsequently
transferred to polyvinylidene difluoride membranes.
After being blocked with TBST [20 mM Tris (pH7.5),
150 mM NaCl, 0.01% Tween-20] containing 5% non-fat
dry milk for 1 hour at room temperature, membranes
were probed with an appropriate antibody overnight at
4°C followed by a horseradish peroxidase (HRP)-linked
goat anti-mouse or anti-rabbit antibodies at room tem-
perature for 1 hour. The membranes were analyzed
using super ECL detection reagent (Applygen, Beijing,
China).
The following antibodies were used: NDRG2 (dilution
1:500; prepared by Department of Immunology, FMMU)
[12], cyclin D1, cyclin E, cyclin D2, cyclin D3 and
cyclin-dependent kinase (cdk) 2 (dilution 1:200, Santa
C r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ) ,p 5 3( d i l u t i o n
1:500; BD Biosciences, San Jose, CA), anti-b-actin (dilu-
tion 1:5000, Sigma Chemical Company, St. Louis, MO).
Cell survival assays
Briefly, cells were seeded at an initial density of 5 × 10
4
cells/ml in a 96-well plate for 24 h. After transfection,
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
l i u mb r o m i d e )w a sa d d e di n t oe a c hw e l la taf i n a lc o n -
centration of 0.5 mg/ml. The insoluble formazan was
collected, dissolved in dimethylsulfoxide and measured
with an ELISA reader (Bio-Rad, USA) at a wavelength
of 570 nm.
RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR)
RNA isolation was performed using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
ture’s protocol. SuperScript Preamplification System
(Gibco BRL, Gaithersburg, MD) was used for cDNA
synthesis. Two microgramme of cDNA was used as a
template for PCR reaction. The following primers were
u s e d :G A P D H :f o r w a r d5 ′-GTC AGT GGT GGA CCT
GAC CT-3′ and reverse 5′-AGG GGT CTA CAT GGC
AAC TG-3′; p53: forward 5′-TAC TCC CCT GCC CTC
AAC AAG A -3′ and reverse 5′-CTT AGC ACC TGA
AGG GTG AAA TAT TC-3′, and NDRG2: forward 5′-
ATG GCG GAG CTG CAG GAG GTG-3′ and reverse
5′-AAC AAG GGC CAT TCA ACA GGA GAC-3′.T h e
cycling conditions were as follows: initial denaturantion
(5 minutes at 94°C), followed by the appropriate number
of 26 cycles of denaturation (94°C, 30 seconds), anneal-
ing (GAPDH, 30 seconds at 60°C; p53, 30 seconds at
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(30 seconds at 72°C), and a final extension (10 minutes
at 72°C). The samples were visualized by electrophoresis
in 1.2% agarose gel and ethidium bromide.
Cell Cycle and apoptosis Analysis
Flow cytometry analysis was performed as described.
Cells were seeded overnight on 60-mm-diameter plates
in a complete medium, placed in a serum-free medium
for 48 hours to synchronize the cells, and then kept
again in the complete medium. At 24 hours, cells were
recovered. After washing with ice-cold PBS, cells were
suspended in about 0.5 ml of 70% alcohol and kept at 4°
C for 30 minutes. The suspension was filtered through a
50-mm nylon mesh, and the DNA content of stained
nuclei was analyzed by a flow cytometer (EPICS XL;
Coulter, Miami FL). Cell cycle was analyzed using Mul-
ticycle-DNA Cell Cycle Analyzed Software (FACScan,
Becton Dickinson, San Jose, CA). The proliferous index
(PI) was calculated as: PI = (S + G2)/(S + G2 + G1).
Apoptosis index was measured using Annexin V-FITC
apoptosis detection kit (Sigma) and subsequently ana-
lyzed by flow cytometry. Each experiment was per-
formed in triplicate [13,14].
Statistical Analysis
All statistical analyses were performed using the SPSS
16.0 statistical software package (SPSS, Chicago, IL).
The differences in apoptosis index between groups were
compared using one-way analysis of variance, and data
were expressed as mean ± SEM. Statistical difference
was accepted at P < 0.05.
Results
Validation of recombinant adenovirus
The pET44a-NDRG2 plasmid and 1.2 kb NDRG2 gene
released from plasmid by Sal I—Hind III restriction
enzyme digestion were shown in Fig. 1A. The target seg-
ment in AdEasy-GFP-NDRG2 was detected by PCR.
Results of electrophoresis on PCR amplification of the
target segment in AdEasy-GFP-NDRG2 are shown in
Fig. 1B. Five clones were picked. Titers of the adenoviral
stocks were 3.1 × 10
8 cfu/ml.
NDRG2 Inhibits CCRCC cell Proliferation
To elucidate the functional role of NDRG2 in renal
tumorigenesis, we examined the effect of exogenous
expression of NDRG2 on the malignant phenotype of
CCRCC cells, A-498. Western blotting revealed that A-
498 expressed NDRG2 when infected by recombinant
adenovirus pAd-GFP-NDRG2 (Fig. 2A).
We then tested the effect of NDRG2 on the Prolifera-
tion of A-498 cells. Growth curves were compared in a
medium containing 10% fetal calf serum, the curves for
cells expressed NDRG2 was significantly lower than
those for control cells(P < 0.05; Fig. 2B). This suggested
that NDRG2 had the potential to inhibit the prolifera-
tion of CCRCC cells.
NDRG2 Induces the Cell Cycle Arrest and apoptosis of
CCRCC Cells
To further investigate the mechanism by which NDRG2
inhibits CCRCC cell growth, we studied the effects of
NDRG2 expression on the cell cycle by fluorescence
activated cell sorter analysis (FASC). The results of the
cell cycle showed that 25.00% of cells expressed NDRG2
were in S-phase compared to 40.67% of control cells,
whereas 62.08% of cells expressed NDRG2 were in G1-
phase compared to 54.39% of control cells (P < 0.05,
Fig. 3A). In addition, FASC also revealed that there
were much more apoptotic cells in NDRG2 -expressing
cells than in the controls (P < 0.01, Fig. 3B). We then
investigated the mechanism by which NDRG2 induced
cell cycle arrest in CCRCC cells. Cell cycle effectors
were examined by western blot analysis (Fig. 3C). Our
results indicated that upregulation of NDRG2 protein
was associated with a reduction in cyclin D1, cyclin E
proteins, whereas cyclinD2, cyclinD3 and cdk2 were not
affected.
Figure 1 Validation of recombinant adenovirus. (A) The pET44a-
NDRG2 plasmid with and without digestion by by Sal I—Hind III
restriction enzyme were shown. (B) The PCR product of target
segment in AdEasy-GFP-NDRG2.
Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:103
http://www.jeccr.com/content/29/1/103
Page 3 of 7p53 up-regulates NDRG2 expression in CCRCC cells
Bioinformatics analysis suggested that there was a p53
binding site in upstream of NDRG2 promoter. To inves-
tigate whether NDRG2 expression was regulated by p53,
we first infected A-498 cells with recombinant adeno-
virus Ad-p53. Both RT-PCR and Western blot revealed
that A-498 cells expressed p53 at higher level when
infected transfected with Ad-p53 (Fig. 4). We then
examined NDRG2 expression in these cells. NDRG2
mRNA was very low in A-498 or cells transfected with
Ad-lacZ but was highly upregulated in cells expressed
Ad-p53, and this upregulation was dose dependent.
Western blot confirmed that NDRG2 protein was upre-
gulated by p53 (Fig. 4).
Discussion
The treatment of renal cancer is challenging due to its
strong resistance to conventional cancer therapy. The
Figure 2 NDRG2 inhibits the proliferation of CCRCC cells. (A) Tthe protein expression was detected by Western blotting. (B) The proliferation
of A-498 cells was detected by MTT.* P < 0.05.
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and apoptosis were detected by FASC. (C) The cell cycle protein were examined by western blot analysis.
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mainly arise from changes in some key genes that are
related to cell proliferation, apoptosis and genomic sta-
bility. Therefore, it is important to identify more genes
specifically related to renal cell carcinoma, which may
expand our understanding of this disease and assist in
the development of new targets for the therapy and
diagnostic indicators. In our previous studies, NDRG2
positive expression found in CCRCC specimens was
30.3% (40/132), which was significantly lower than the
91.67% (121/132) in their adjacent tissues. These data
indicated that decreased of NDRG2 expression is a fre-
quent event in human renal cell carcinoma.
To determine whether the ectopic expression of
NDRG2 could modulate the proliferation of renal cancer
cells, duplication-defective adenovirus was used as the
vehicle. The results of verification showed that the
NDRG2 effectively incorporated into the plasmid of the
recombinant adenovirus. This recombinant adenovirus
had a high transfection on A-498 renal cancer cells and
successfully expressed NDRG2 at a high level. We found
that NDRG2 significantly inhibited renal cancer cell pro-
liferation. Then we demonstrated that NDRG2 tumor-
suppressor activity is mediated by the inhibition of cell
cycle progression with increased accumulation of cancer
cells in G1-phase and a corresponding reduction of cells
in the S-phase of the cell cycle in the A-498 renal can-
cer cells. Very recently, Kim et al. reported that NDRG2
suppressed cell proliferation through down-regulation of
AP-1 activity in human colon carcinoma cells[15]. They
found that NDRG2 modulated intracellular signals to
control cell cycle through the regulation of cyclin D1
expression via phosphorylation pathway, which might
helped to explain alterations of cell cycle effectors in
our research.
Also clearly in our studies, NDRG2 induced renal can-
cer cell apoptosis. NDRG2 was lately reported to be
involved in hypoxia-induced apoptosis or fas-mediated
cell death in different cancer cell types [16,17]. Investi-
gations carried out by Liu et al. indicated that NDRG2
was a new target gene that is regulated by p53 and
NDRG2 mRNA and protein levels can be upregulated in
a p53-dependent manner [13,18], which were also
observed in our work. They further reported that silen-
cing of NDRG2 attenuates p53-mediated apoptosis.
These data strongly suggested that NDRG2 was an
important factor in regulating tumor cell apoptosis.
Conclusions
Our results show that enforced NDRG2 expression sig-
nificantly inhibited RCC cell growth, and induced apop-
tosis in human renal carcinoma cells. We also observed
that NDRG2 expression could be upregulated by p53 in
dose dependent manner. Further research may help
design an effective therapeutic modality to control renal
cancer.
Abbreviations
NDRG2: N-myc downstream-regulated gene 2; CCRCC: clear cell renal cell
carcinoma; RT-PCR: Reverse transcription-polymerase chain reaction.
Acknowledgements
The Project Supported by Natural Science Basic Research Plan in Shaanxi
Province of China (Program No. 2009JM4003-3)
Author details
1Department of Urology, Tangdu Hospital, the Fourth Military Medical
University, Xi’an, China.
2Cell Engineering Research Centre, the Fourth Military
Medical University, Xi’an, China.
3Department of Operation Room, Tangdu
Hospital, the Fourth Military Medical University, Xi’an, China.
4Department of
General Surgery, Tangdu Hospital, the Fourth Military Medical University,
Xi’an, China.
5Department of Biochemistry and Molecular Biology, the Fourth
Military Medical University, Xi’an, China.
Authors’ contributions
TYB and LBY contributed to the conception and design of the study; JJM
performed research; XJ and HDZ contributed to collection and assembly of
data; JJM and CGL contributed to data analysis and manuscript writing. All
authors have read and approved the final manuscript.
Figure 4 p53 up-regulates NDRG2 expression in CCRCC cells.
(A) and (B) RT-PCR and Western blot analysis were used to detect
the p53 and NDRG2 mRNA and protein expression levels. Ad-lacZ
was used as negative control.
Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:103
http://www.jeccr.com/content/29/1/103
Page 6 of 7Competing interests
The authors declare that they have no competing interests.
Received: 18 June 2010 Accepted: 30 July 2010 Published: 30 July 2010
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007.
CA Cancer J Clin 2007, 57:43-66.
2. Boulkroun S, Fay M, Zennaro MC, Escoubet B, Jaisser F, Blot-Chabaud M,
Farman N, Courtois-Coutry N: Characterization of rat NDRG2 (N-Myc
downstream regulated gene 2), a novel early mineralocorticoid-specific
induced gene. J Biol Chem 2002, 277:31506-31515.
3. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, et al:
N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell
proliferation. Int J Cancer 2003, 106:342-347.
4. Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F: Characterization and
expression of three novel differentiation-related genes belong to the
human NDRG gene family. Mol Cell Biochem 2002, 229:35-44.
5. Mitchelmore C, Buchmann-Moller S, Rask L, West MJ, Troncoso JC,
Jensen NA: NDRG2: a novel Alzheimer’s disease associated protein.
Neurobiol Dis 2004, 16:48-58.
6. Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, Chang YS, Paik SG,
Lim JS: Expression and regulation of NDRG2 (N-myc downstream
regulated gene 2) during the differentiation of dendritic cells. FEBS Lett
2003, 553:413-418.
7. Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G,
Mauch C, Lichter P, Angel P: Identification of novel tumour-associated
genes differentially expressed in the process of squamous cell cancer
development. Oncogene 2006, 25:111-121.
8. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G,
Gutmann DH, Perry A: Integrative genomic analysis identifies NDRG2 as a
candidate tumor suppressor gene frequently inactivated in clinically
aggressive meningioma. Cancer Res 2005, 65:7121-7126.
9. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A,
Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-
grade glioma predict prognosis, delineate a pattern of disease
progression, and resemble stages in neurogenesis. Cancer Cell 2006,
9:157-173.
10. Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, Zhang W, Zhao H, Yao L:
Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull
2008, 31:1316-1320.
11. Kanai F: Transcriptional targeted gene therapy for hepatocellular
carcinoma by adenovirus vector. Mol Biotechnol 2001, 18:243-250.
12. Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB, Li X,
Shen L, et al: Expression analysis of the NDRG2 gene in mouse
embryonic and adult tissues. Cell Tissue Res 2006, 325:67-76.
13. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Wu Y, Ji S, Zhang Y, Yang A,
et al: N-Myc downstream-regulated gene 2 is involved in p53-mediated
apoptosis. Nucleic Acids Res 2008, 36:5335-5349.
14. Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K: NDRG2
is a candidate tumor-suppressor for oral squamous-cell carcinoma.
Biochem Biophys Res Commun 391:1785-1791.
15. Kim YJ, Yoon SY, Kim JT, Choi SC, Lim JS, Kim JH, Song EY, Lee HG, Choi I,
Kim JW: NDRG2 suppresses cell proliferation through down-regulation of
AP-1 activity in human colon carcinoma cells. Int J Cancer 2009, 124:7-15.
16. Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH, Yang Y, Lim JS,
Lee HG: Expression of NDRG2 is related to tumor progression and
survival of gastric cancer patients through Fas-mediated cell death. Exp
Mol Med 2007, 39:705-714.
17. Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, et al:
NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced
apoptosis in A549 cells. Cell Physiol Biochem 2008, 21:239-250.
18. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y, Ji S, Zhang Y,
et al: N-Myc downstream-regulated gene 2 is involved in p53-mediated
apoptosis. Nucleic Acids Res 2008, 36:5335-5349.
doi:10.1186/1756-9966-29-103
Cite this article as: Ma et al.: NDRG2 suppresses the proliferation of
clear cell renal cell carcinoma cell A-498. Journal of Experimental &
Clinical Cancer Research 2010 29:103.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ma et al. Journal of Experimental & Clinical Cancer Research 2010, 29:103
http://www.jeccr.com/content/29/1/103
Page 7 of 7